Skip to main content
Figure 3 | Cardiovascular Diabetology

Figure 3

From: Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

Figure 3

A. Residual risk in people with diabetes and atherogenic dyslipidemia: effect of standard-dose statin therapy, pooled data [6674]. Red column represents the coronary risk in the people with diabetes and atherogenic dyslipidemia treated by statins as compared to placebo (blue column), and the patients without diabetes and atherogenic dyslipidemia treated by statins (green column). The yellow arrows demonstrate the additional coronary risk of the diabetic patients with atherogenic dyslipidemia treated by statins. B. Residual risk in people with diabetes and atherogenic dyslipidemia: effect of intenesive statin therapy. The hypothetical extra benefit obtained by intensive statin therapy based on the meta-analysis (it is presented by the white box)[80]. Residual risk is still remained considerable.

Back to article page